Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEN3014 in relapsed or refractory multiple myeloma and other hematologic malignancies
NL-OMON52305Phase 2Terminated
- Sponsor
- Genmab
- Start
- Jan 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of gen3014 and daratumumab in multiple myeloma (MM), acute myeloid leukemia (AML) and diffuse large B-cell lymphoma (DLBCL) (8 arms), sponsored by Genmab. Started Jan 2022; status: terminated.
02
Drugs
gen3014daratumumab
03
Conditions
multiple myeloma (MM)acute myeloid leukemia (AML)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NL-OMON52305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52305.